Amgen Inc. is making a strategic shift from a defensive dividend stock to a growth-focused biotechnology powerhouse, backed by a comprehensive $3.96 billion capital restructuring plan. The company is forecasting significant revenue growth, projecting $37.4 billion by 2028, fueled by a solid performance in 2025 with $9.9 billion in revenue. Analysts have responded positively, granting Amgen a 'Strong Buy' rating as it aims to capitalize on opportunities in the obesity market, despite facing challenges from drug pricing pressures and biosimilar competition.
“The new multi-decade bond maturities and change-of-control protection highlight how Amgen is structuring its capital stack to support long-term investment plans while balancing creditor protections.”
“Amgen’s narrative projects $37.4 billion in revenue and $8.2 billion in earnings by 2028. This requires 2.3% yearly revenue growth and about a $1.6 billion earnings increase from $6.6 billion today.”
“AMGN is attracting bullish positioning after a trader sold 1,000 June 18, 2026 $340 put contracts for $9.00 each, collecting $900,000 in upfront premium.”
“However, REGN underperformed compared to its rival, Amgen Inc. (AMGN), which gained 26.9% over the past 52 weeks and 18.6% on a YTD basis.”
“Nevertheless, analysts remain strongly optimistic about its prospects. The stock has a consensus rating of 'Strong Buy' from the 27 analysts covering it, and the mean price target of $870.35 suggests a 11.3% premium to its current levels.”
“Amgen Inc AMGN 44% 2.56% 11.1% per year”
“Amgen Inc AMGN 44% 2.56% 11.1% per year”
“Amgen Inc AMGN 44% 2.56% 11.1% per year”
“The following Dow stocks, though — in no particular order — seem to have a healthy record of dividend growth, sustainable payout ratios, and decent yields, meaning their stocks are relatively affordable for the dividends they provide: ... Amgen ...”
“In comparison, rival Amgen Inc. (AMGN) has outpaced PFE stock. AMGN stock has returned 17% on a YTD basis and 23.6% over the past 52 weeks.”
“With a market cap of $206.4 billion, Amgen Inc. (AMGN) is a global biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics for serious diseases worldwide.”
“Shares of Amgen jumped 8.2% following its Q4 2025 results on Feb. 3, reporting stronger-than-expected $9.9 billion in revenue and adjusted EPS of $5.29.”